Cosmo Bio Company,Limited

TSE:3386 Stock Report

Market Cap: JP¥6.8b

Cosmo Bio CompanyLimited Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Cosmo Bio CompanyLimited.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth7.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Cosmo Bio CompanyLimited's (TSE:3386) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 12
Cosmo Bio CompanyLimited's (TSE:3386) Shareholders Have More To Worry About Than Only Soft Earnings

Cosmo Bio CompanyLimited (TYO:3386) Is Experiencing Growth In Returns On Capital

May 09
Cosmo Bio CompanyLimited (TYO:3386) Is Experiencing Growth In Returns On Capital

Cosmo Bio Company,Limited (TYO:3386) Vies For A Place In Your Dividend Portfolio: Here's Why

Mar 23
Cosmo Bio Company,Limited (TYO:3386) Vies For A Place In Your Dividend Portfolio: Here's Why

Cosmo Bio Company,Limited's (TYO:3386) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 02
Cosmo Bio Company,Limited's (TYO:3386) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Will The ROCE Trend At Cosmo Bio CompanyLimited (TYO:3386) Continue?

Feb 07
Will The ROCE Trend At Cosmo Bio CompanyLimited (TYO:3386) Continue?

Does Cosmo Bio CompanyLimited's (TYO:3386) Share Price Gain of 30% Match Its Business Performance?

Jan 17
Does Cosmo Bio CompanyLimited's (TYO:3386) Share Price Gain of 30% Match Its Business Performance?

Should Cosmo Bio Company,Limited (TYO:3386) Be Part Of Your Dividend Portfolio?

Dec 23
Should Cosmo Bio Company,Limited (TYO:3386) Be Part Of Your Dividend Portfolio?

Do Fundamentals Have Any Role To Play In Driving Cosmo Bio Company,Limited's (TYO:3386) Stock Up Recently?

Dec 02
Do Fundamentals Have Any Role To Play In Driving Cosmo Bio Company,Limited's (TYO:3386) Stock Up Recently?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cosmo Bio CompanyLimited has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TSE:3386 - Analysts future estimates and past financials data (JPY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20249,872367N/AN/AN/A
6/30/20249,64233966198N/A
3/31/20249,455408N/AN/AN/A
12/31/20239,340442636736N/A
9/30/20239,303429N/AN/AN/A
6/30/20239,269471538652N/A
3/31/20239,334415N/AN/AN/A
12/31/20229,553517180284N/A
9/30/20229,477576N/AN/AN/A
6/30/20229,507654424528N/A
3/31/20229,400770N/AN/AN/A
12/31/20219,231737507648N/A
9/30/20219,147714N/AN/AN/A
6/30/20218,981714553668N/A
3/31/20218,550775N/AN/AN/A
12/31/20208,092674738803N/A
9/30/20207,821553N/AN/AN/A
6/30/20207,742508829923N/A
3/31/20207,862322N/AN/AN/A
12/31/20197,590237378549N/A
9/30/20197,499317N/AN/AN/A
6/30/20197,257256385603N/A
3/31/20197,113230N/AN/AN/A
12/31/20187,261260768908N/A
9/30/20187,189171N/AN/AN/A
6/30/20187,167156N/A423N/A
3/31/20187,159270N/AN/AN/A
12/31/20177,068237N/A89N/A
9/30/20177,027217N/AN/AN/A
6/30/20177,143261N/A439N/A
3/31/20177,309190N/AN/AN/A
12/31/20167,427254N/A573N/A
9/30/20167,559363N/AN/AN/A
6/30/20167,507342N/A252N/A
3/31/20167,351286N/AN/AN/A
12/31/20157,357230N/A129N/A
9/30/20157,424190N/AN/AN/A
6/30/20157,394163N/A97N/A
3/31/20157,371201N/AN/AN/A
12/31/20147,235201N/A297N/A
9/30/20147,112203N/AN/AN/A
6/30/20147,167310N/A403N/A
3/31/20147,149297N/AN/AN/A
12/31/20137,050313N/A126N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 3386's forecast earnings growth is above the savings rate (0.3%).

Earnings vs Market: Insufficient data to determine if 3386's earnings are forecast to grow faster than the JP market

High Growth Earnings: Insufficient data to determine if 3386's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 3386's revenue is forecast to grow faster than the JP market.

High Growth Revenue: Insufficient data to determine if 3386's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 3386's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y